转移性子宫癌患者新辅助化疗后微创手术的采用情况
研究利用美国国家癌症数据库分析2010至2017年接受新辅助化疗的IV期子宫癌患者,比较开腹与微创肿瘤减灭术的生存结局;微创手术使用率从16.2%升至40.4%,倾向评分加权后微创手术与生存无显著关联(HR=0.90,95%CI 0.71-1.14)。
要点
- 微创肿瘤减灭术使用率从2010年16.2%增至2017年40.4%(P<0.001)。
- 微创手术组中位总生存28个月,开腹组24.3个月。
- 倾向评分加权后微创手术与生存无显著关联(HR=0.90,95%CI 0.71-1.14)。
核心结论
- 在接受新辅助化疗的IV期子宫癌患者中,微创肿瘤减灭术的使用率在增加。
- 与开腹手术相比,微创手术似乎不产生负面的生存影响。
研究设计与样本
- 利用美国国家癌症数据库识别2010至2017年诊断并接受新辅助化疗的IV期子宫癌女性。
- 在接受间歇性肿瘤减灭术的患者中,比较开腹手术与微创手术的总生存,并采用逆概率治疗加权倾向评分分析校正混杂因素。
主要发现
- 共识别1618例女性,31.1%接受了微创间歇性肿瘤减灭术。
- 微创手术使用率从2010年16.2%增至2017年40.4%(P<0.001)。
- 更近的诊断年份和在综合癌症中心手术与微创手术使用增加相关(P<0.05)。
- 浆液性、透明细胞和癌肉瘤患者(相较于子宫内膜样肿瘤)以及医疗补助保险覆盖者(相较于商业保险)接受微创手术的可能性更低(P<0.05)。
- 微创手术组中位总生存28个月(95%CI 23.7-30.7),开腹组24.3个月(95%CI 22.3-26.1);倾向评分平衡后微创手术与生存无显著关联(HR=0.90,95%CI 0.71-1.14)。
关键数值与推荐
- 微创手术使用率从2010年16.2%增至2017年40.4%(P<0.001)。
- 微创手术组中位总生存28个月(95%CI 23.7-30.7),开腹组24.3个月(95%CI 22.3-26.1)。
- 倾向评分加权后微创手术与生存无显著关联(HR=0.90,95%CI 0.71-1.14)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Utilization of neoadjuvant chemotherapy (NACT) for advanced stage uterine cancer is increasing. We analyzed the use and outcomes of open versus minimally invasive surgery (MIS) for women with stage IV uterine cancer who received NACT and underwent IDS. METHODS: The National Cancer Database was used to identify women with stage IV uterine cancer diagnosed from 2010 to 2017 and treated with NACT. Among women who underwent IDS, overall survival (OS) was compared between those who underwent laparotomy vs a minimally invasive approach. To account for imbalances in confounders, a propensity score analysis using inverse probability of treatment weighting (IPTW) was performed. RESULTS: A total of 1618 women were identified. Minimally invasive IDS was performed in 31.1% and increased from 16.2% in 2010 to 40.4% in 2017 (P < 0.001). More recent year of diagnosis and performance of surgery at a comprehensive cancer center were associated with increased use of MIS (P < 0.05). Women with serous and clear cell tumors, and carcinosarcomas (compared to endometrioid tumors), as well as Medicaid coverage (compared to commercial insurance) were less likely to undergo an MIS approach (P < 0.05). The median OS was 28 months (95% CI 23.7-30.7) and 24.3 months (95% CI 22.3-26.1) for MIS and laparotomy, respectively. After propensity score balancing, there was no association between the use of MIS and survival (HR = 0.90, 95% CI 0.71-1.14). CONCLUSIONS: Among women with stage IV uterine cancer treated with NACT performance of minimally invasive debulking surgery is increasing. Compared to laparotomy, MIS does not appear to negatively impact survival.
引用
- Zhou ZN, Chen L, Melamed A, et al. Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. Gynecol Oncol. 2021. PMID: 34920885. doi:10.1016/j.ygyno.2021.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。